Should Adjuvant Chemotherapy be used in Elderly Women (≥70 Years) with Breast Cancer? Contra

Abstract

Get full access to this article

View all access options for this article.

References

Parkin

D.M.

: Cancer burden in the year 2000. The global picture. Eur J Cancer, 37: S4–66, 2001.

Satariano

W.A.

: The effect of comorbidity on 3-year survival of women with primary BC. Ann Int Med, 120: 104–110, 1994.

Anonymous: Poly chemotherapy for early ca: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 352: 930, 1998.

Anonymous: Tamoxifen for early ca: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 351: 1451, 1998.

Desh

C.E.

: Should the elderly receive chemotherapy for node negative breast cancer? A cost-effectiveness analysis ex-aminig total and active life-expectancy outcomes. J Clin Oncol, 11: 777, 1993.

German

R.S.

: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using dosing doses based on creatinine clearance. J Clin Oncol, 2: 1404, 1984.

Giovanazzi-Bannon

: Treatment tolerance of elderly cancer patients entered into phase 2 clinical trials: an Illinois Cancer Centerstudy. J Clin One, 12: 2447, 1994.

Crivellari

: Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol, 18: 1412–1422, 2000.

Muss

H.B.

: Breast cancer in the elderly: the role of systemic adjuvant therapy, Asco, 2001.